Titlebook: Biopharma in China; Innovation, Trends a Sven Agten,Ben Wu Book 2024 The Author(s), under exclusive license to Springer Nature Singapore Pt

只看該作者 · 發(fā)表于 2025-3-23 19:13:23

Sven Agten,Ben WuExplores legal issues around medicine in China.Examines the growing biopharma industry in China.Offers insights for professionals

只看該作者 · 發(fā)表于 2025-3-24 00:15:51

只看該作者 · 發(fā)表于 2025-3-24 06:04:22

只看該作者 · 發(fā)表于 2025-3-24 08:03:01

只看該作者 · 發(fā)表于 2025-3-24 12:44:56

只看該作者 · 發(fā)表于 2025-3-24 18:28:29

只看該作者 · 發(fā)表于 2025-3-24 21:00:28

只看該作者 · 發(fā)表于 2025-3-25 02:29:28

Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class,eld of antibodies. Learning from past experiences and urged on by their investors, since 2020 an increasing number of Chinese biopharmas have embarked on a strategy to develop first-in-class drugs with global potential using novel technologies. Especially during the pandemic, China became host to a

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 12:27
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved